[SCHEDULE 13G/A] Acrivon Therapeutics, Inc. SEC Filing
This Schedule 13G/A reports that Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands jointly beneficially own 2,122,605 shares of Acrivon Therapeutics common stock, representing 6.8% of the outstanding shares based on 31,355,361 shares reported by the issuer. The filing shows no sole voting or dispositive power and indicates shared voting and dispositive power over the reported shares, consistent with a passive investor position.
The filing names the reporting entities, identifies their places of organization (Cayman Islands, Delaware and United States), provides the issuer's principal office address, and includes a certification that the securities were not acquired to change or influence control of the issuer.
Questo Schedule 13G/A segnala che Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC e Frank M. Sands detengono congiuntamente 2,122,605 azioni ordinarie di Acrivon Therapeutics, pari al 6.8% delle azioni in circolazione, calcolato su 31,355,361 azioni riportate dall'emittente. La comunicazione indica di non avere potere di voto o di disposizione esclusivo e segnala invece potere di voto e di disposizione condiviso sulle azioni dichiarate, coerente con una posizione di investitore passivo.
La comunicazione nomina le entit脿 che presentano la dichiarazione, ne indica le sedi di costituzione (Isole Cayman, Delaware e Stati Uniti), fornisce l'indirizzo della sede principale dell'emittente e include una certificazione che i titoli non sono stati acquisiti per modificare o influenzare il controllo dell'emittente.
Este Schedule 13G/A informa que Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC y Frank M. Sands poseen conjuntamente 2,122,605 acciones ordinarias de Acrivon Therapeutics, lo que representa el 6.8% de las acciones en circulaci贸n, sobre la base de 31,355,361 acciones declaradas por el emisor. La presentaci贸n muestra que no poseen poder de voto o de disposici贸n exclusivo e indica que tienen poder de voto y de disposici贸n compartido sobre las acciones informadas, coherente con una posici贸n de inversor pasivo.
La presentaci贸n identifica a las entidades informantes, se帽ala sus lugares de constituci贸n (Islas Caim谩n, Delaware y Estados Unidos), facilita la direcci贸n de la oficina principal del emisor e incluye una certificaci贸n de que los valores no se adquirieron para cambiar o influir en el control del emisor.
鞚� Schedule 13G/A電� Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC 氚� Frank M. Sands臧� 瓿惦彊鞙茧 Acrivon Therapeutics 氤错喌欤� 2,122,605欤茧ゼ 氤挫湢頃橁碃 鞛堨溂氅�, 氚滍枆鞚胳澊 氤搓碃頃� 31,355,361欤茧ゼ 旮办鞙茧 氚滍枆欤检嫕鞚� 6.8%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞝涤稖靹滊电� 雼弲鞚� 鞚橁舶甓� 霕愲姅 觳橂秳甓� 鞐嗢潓鞚� 氇呾嫓頃橁碃, 氤搓碃霅� 欤检嫕鞐� 雽�頃� 瓿惦彊鞚� 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨潓鞚� 雮橅儉雮挫柎 靾橂彊鞝� 韴瀽鞛� 鞛呾灔瓿� 鞚检箻頃╇媹雼�.
靹滊電� 鞁犼碃欤检泊霌れ潉 氇呾嫓頃橁碃 攴鸽摛鞚� 靹る歆�(旒�鞚措Ж 鞝滊弰, 雿鸽澕鞗柎 氚� 氙戈淡)毳� 旮办灛頃橂┌, 氚滍枆鞚胳潣 氤胳偓 欤检唽毳� 鞝滉车頃橁碃 頃措嫻 歃濌秾鞚� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃橂姅 鞚胳鞚� 韽暔頃╇媹雼�.
Ce Schedule 13G/A signale que Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC et Frank M. Sands d茅tiennent conjointement 2,122,605 actions ordinaires d'Acrivon Therapeutics, repr茅sentant 6.8% des actions en circulation, sur la base de 31,355,361 actions d茅clar茅es par l'茅metteur. le d茅p么t indique aucun pouvoir de vote ou de disposition exclusif et pr茅cise qu'il existe un pouvoir de vote et de disposition partag茅 sur les actions d茅clar茅es, coh茅rent avec une position d'investisseur passif.
Le d茅p么t nomme les entit茅s d茅clarantes, identifie leurs lieux de constitution (卯les Ca茂mans, Delaware et 脡tats-Unis), fournit l'adresse du si猫ge principal de l'茅metteur et inclut une certification selon laquelle les titres n'ont pas 茅t茅 acquis dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Dieses Schedule 13G/A meldet, dass Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC und Frank M. Sands gemeinsam 2,122,605 Aktien der Stammaktien von Acrivon Therapeutics halten, was 6.8% der ausstehenden Aktien entspricht, basierend auf 31,355,361 vom Emittenten gemeldeten Aktien. Die Einreichung weist keine alleinige Stimm- oder Verf眉gungsbefugnis aus und gibt an, 眉ber die gemeldeten Aktien geteilte Stimm- und Verf眉gungsbefugnis zu verf眉gen, was einer passiven Investorenposition entspricht.
Die Einreichung nennt die meldenden Stellen, gibt deren Gr眉ndungsorte an (Kaimaninseln, Delaware und Vereinigte Staaten), nennt die Gesch盲ftsadresse des Emittenten und enth盲lt eine Best盲tigung, dass die Wertpapiere nicht erworben wurden, um die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen.
- Reports a material ownership position: 2,122,605 shares representing 6.8% of Acrivon's outstanding common stock.
- Declared passive intent: Item 10 certification states the securities were not acquired to change or influence control, consistent with a Schedule 13G passive disclosure.
- Transparent joint filing: Identifies reporting persons, organizational jurisdictions and principal business address, aiding investor clarity.
- None.
Insights
TL;DR: Sands Capital reports a meaningful passive stake of 6.8% (2.12M shares) in ACRV, with shared voting and dispositive power.
The filing discloses a >5% beneficial ownership position: 2,122,605 shares (6.8%) out of 31,355,361 shares outstanding as reported by the issuer. The reporting persons explicitly record no sole voting or dispositive power, indicating they do not individually control voting decisions. The Item 10 certification states the securities were not acquired to influence control, consistent with a Schedule 13G passive disclosure rather than an activist 13D filing. For investors, this documents a sizable minority economic interest without an expressed intent to seek control.
TL;DR: A 6.8% passive stake by institutional reporting persons is material but filed as passive; governance influence appears limited per this filing.
The joint filing by Sands entities and Frank M. Sands shows shared voting/dispositive authority over 2,122,605 shares and an explicit certification that holdings are not intended to change control. The schedule identifies the reporting structure and organizational jurisdictions (Cayman, Delaware, U.S.), and disclaims sole ownership beyond pecuniary interest. From a governance perspective, the disclosure notifies the market of a significant shareholder while affirming a non-activist posture in this document.
Questo Schedule 13G/A segnala che Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC e Frank M. Sands detengono congiuntamente 2,122,605 azioni ordinarie di Acrivon Therapeutics, pari al 6.8% delle azioni in circolazione, calcolato su 31,355,361 azioni riportate dall'emittente. La comunicazione indica di non avere potere di voto o di disposizione esclusivo e segnala invece potere di voto e di disposizione condiviso sulle azioni dichiarate, coerente con una posizione di investitore passivo.
La comunicazione nomina le entit脿 che presentano la dichiarazione, ne indica le sedi di costituzione (Isole Cayman, Delaware e Stati Uniti), fornisce l'indirizzo della sede principale dell'emittente e include una certificazione che i titoli non sono stati acquisiti per modificare o influenzare il controllo dell'emittente.
Este Schedule 13G/A informa que Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC y Frank M. Sands poseen conjuntamente 2,122,605 acciones ordinarias de Acrivon Therapeutics, lo que representa el 6.8% de las acciones en circulaci贸n, sobre la base de 31,355,361 acciones declaradas por el emisor. La presentaci贸n muestra que no poseen poder de voto o de disposici贸n exclusivo e indica que tienen poder de voto y de disposici贸n compartido sobre las acciones informadas, coherente con una posici贸n de inversor pasivo.
La presentaci贸n identifica a las entidades informantes, se帽ala sus lugares de constituci贸n (Islas Caim谩n, Delaware y Estados Unidos), facilita la direcci贸n de la oficina principal del emisor e incluye una certificaci贸n de que los valores no se adquirieron para cambiar o influir en el control del emisor.
鞚� Schedule 13G/A電� Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC 氚� Frank M. Sands臧� 瓿惦彊鞙茧 Acrivon Therapeutics 氤错喌欤� 2,122,605欤茧ゼ 氤挫湢頃橁碃 鞛堨溂氅�, 氚滍枆鞚胳澊 氤搓碃頃� 31,355,361欤茧ゼ 旮办鞙茧 氚滍枆欤检嫕鞚� 6.8%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞝涤稖靹滊电� 雼弲鞚� 鞚橁舶甓� 霕愲姅 觳橂秳甓� 鞐嗢潓鞚� 氇呾嫓頃橁碃, 氤搓碃霅� 欤检嫕鞐� 雽�頃� 瓿惦彊鞚� 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨潓鞚� 雮橅儉雮挫柎 靾橂彊鞝� 韴瀽鞛� 鞛呾灔瓿� 鞚检箻頃╇媹雼�.
靹滊電� 鞁犼碃欤检泊霌れ潉 氇呾嫓頃橁碃 攴鸽摛鞚� 靹る歆�(旒�鞚措Ж 鞝滊弰, 雿鸽澕鞗柎 氚� 氙戈淡)毳� 旮办灛頃橂┌, 氚滍枆鞚胳潣 氤胳偓 欤检唽毳� 鞝滉车頃橁碃 頃措嫻 歃濌秾鞚� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃橂姅 鞚胳鞚� 韽暔頃╇媹雼�.
Ce Schedule 13G/A signale que Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC et Frank M. Sands d茅tiennent conjointement 2,122,605 actions ordinaires d'Acrivon Therapeutics, repr茅sentant 6.8% des actions en circulation, sur la base de 31,355,361 actions d茅clar茅es par l'茅metteur. le d茅p么t indique aucun pouvoir de vote ou de disposition exclusif et pr茅cise qu'il existe un pouvoir de vote et de disposition partag茅 sur les actions d茅clar茅es, coh茅rent avec une position d'investisseur passif.
Le d茅p么t nomme les entit茅s d茅clarantes, identifie leurs lieux de constitution (卯les Ca茂mans, Delaware et 脡tats-Unis), fournit l'adresse du si猫ge principal de l'茅metteur et inclut une certification selon laquelle les titres n'ont pas 茅t茅 acquis dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Dieses Schedule 13G/A meldet, dass Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC und Frank M. Sands gemeinsam 2,122,605 Aktien der Stammaktien von Acrivon Therapeutics halten, was 6.8% der ausstehenden Aktien entspricht, basierend auf 31,355,361 vom Emittenten gemeldeten Aktien. Die Einreichung weist keine alleinige Stimm- oder Verf眉gungsbefugnis aus und gibt an, 眉ber die gemeldeten Aktien geteilte Stimm- und Verf眉gungsbefugnis zu verf眉gen, was einer passiven Investorenposition entspricht.
Die Einreichung nennt die meldenden Stellen, gibt deren Gr眉ndungsorte an (Kaimaninseln, Delaware und Vereinigte Staaten), nennt die Gesch盲ftsadresse des Emittenten und enth盲lt eine Best盲tigung, dass die Wertpapiere nicht erworben wurden, um die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen.
FAQ
How many ACRV shares does Sands Capital report owning?
What percentage of Acrivon (ACRV) does that represent?
Does any reporting person have sole voting or dispositive power over these shares?
Are the holdings presented as passive or intended to influence control?
Which entities filed the Schedule 13G/A for ACRV?
